AI Insight
Researchers at PSI and the University of Zurich have conducted detailed structural analysis of the BRAF protein, which is mutated in approximately 50% of malignant melanomas and 7% of all other cancers. The study reveals new insights into how BRAF mutations disrupt normal cell division regulation, leading to uncontrolled cell multiplication. This structural information advances understanding of the protein's complex regulatory mechanisms.
Why it matters
The detailed structural knowledge of BRAF could enable development of more targeted cancer therapies, particularly for melanoma patients. Understanding the protein's regulation mechanism may help identify new drug targets to block the abnormal signaling that drives cancer cell growth.
Understand the Science
Malignant melanoma is one of the most dangerous forms of cancer. Around half of melanomas and about 7% of all other cancers carry a mutation in a protein called BRAF. This mutation disrupts the regulation of cell division, causing cells to multiply in an uncontrolled manner. Researchers at PSI and the University of Zurich have now examined the BRAF protein in greater detail, gaining valuable insights into its complex regulation.
Source: New protein structure reveals cancer signaling mechanism and potential drug target